Skip to main navigation
Skip to main content
Skip to Footer
Google Tag Manager
US
Sandoz Site Directory
Our Work
What We Do
Disease Areas
Quality Generics
Biosimilars
Access to Healthcare
About Us
Who We Are
Where We Do Business
Corporate Responsibility
For Novartis Investors
Contact Us
Doing Business Responsibly
Patients & Customers
Report Side Effects
Product Safety Notices
Information for Customers
Products
News
US Press Releases & News
Media Contacts
Publications
Careers
Job Search
Working at Sandoz US
Diversity & Inclusion
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Filter By
2016
July
Media Release
/
Jul 21, 2016
Sandoz launches generic version of Crestor®
Read More
Media Release
/
Jul 13, 2016
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Read More
Media Release
/
Jul 07, 2016
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
Read More
June
Media Release
/
Jun 20, 2016
Sandoz announces plans for five major global biosimilar launches by 2020
Read More
2015
November
Media Release
/
Nov 12, 2015
Generic medicines saved US healthcare system more than USD 250 billion in 2014 alone
Read More
October
Media Release
/
Oct 26, 2015
IMPORTANT INFORMATION ABOUT TEMOZOLOMIDE CAPSULES (GENERIC)
Read More
June
Media Release
/
Jun 19, 2015
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg
Read More
Media Release
/
Jun 04, 2015
Sandoz launches generic version of INTUNIV® extended release tablets in the US
Read More
April
Media Release
/
Apr 16, 2015
Sandoz receives FDA approval for Glatopa™ as the first generic competitor to MS therapy Copaxone® 20mg
Read More
March
Media Release
/
Mar 06, 2015
FDA approves first biosimilar Zarxio™ (filgrastimsndz)
Read More
Search Results Navigation
First page
« first
Previous page
‹ previous
…
Page
5
of 5
Page
6
of 5
Page
7
of 5
Page
8
of 5
Current page
9
of 5
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
Print
Save
You are here
Home
›
News
›
